Home
.
Site map
.
Contact us
.
Disclaimer
.
Privacy policy
About Peplin
Company profile
Company history
Corporate strategy
Products & technology
Research and development
Drug development process
Clinical development
Pre-clinical development
Research
Research programs
Publications
Abstracts
Manufacturing process
Glossary
Target diseases
Actinic keratosis (AK)
Non-melanoma skin cancer (NMSC)
Leukemia
Bladder cancer
Corporate information
Board of directors
Executive management
Corporate directory
Corporate governance
Dermatology clinical advisory board
Investor information
ASX & media releases
PEPTalk
Reports to shareholders
Annual
Half yearly
Quarterly cashflow
Share price information
Securities trading
Major shareholders
FAQs
Links
News reports
PEP
Talk
.................................................................................
PEP
Talk
is Peplin's quarterly report to shareholders since the start of 2005.
Current year
|
Archived 2007
|
Archived 2006
|
Archived 2005
Year ending 30-Jun-2008
588 Kb
© Peplin 2008
